Biologics manufacturing facility
Construction of the National Biologics Manufacturing Centre (NBMC) at Central Park in Darlington, UK, began in April 2014. The facility is used for conducting research on biologic products by promoting collaboration between academia, the National Health Service (NHS) and the industry.
The facility was opened in September 2015 and is managed by Centre for Process Innovation (CPI).
Novasep installed BioSC Lab protein purification technology in the National Biologics Manufacturing Centre in November 2015.
The new NBMC has a total floor space of 5,000m² and is equipped with flexible laboratory and pilot plant areas. It helps companies in the biologics market to produce, demonstrate, prototype and scale-up the next-generation of biologic products, as well as processes and technology. It also helps companies based in the UK to develop a competitive foothold in the growing biologics market.
It will manufacture medicines for treating diseases that include cancer, autoimmune, and hereditary ailments.
The facility has a dedicated space for Good Manufacturing Practices (GMP) process, analytical and technology development, and clean rooms to carry out research. It is also facilitated with state-of-the-art lab equipment. It is designed to feature flexible, open-plan areas and houses offices, and meeting rooms and spaces for training and conferencing.
It was developed with a £38m ($64m) investment by the government as part of the ‘Strategy for UK Life Sciences’ programme initiated in 2011, which promised a £310m investment towards the support of discovery, development and commercialisation of innovative medicines.
The facility is strategically located at Darlington as it is in close proximity to East Coast Mainline for transport facilities. It is also near existing pharmaceutical companies and relevant universities in the north of England.
NBMC’s construction created new jobs for the region and helps to enhance the local economy, as well as the competitiveness of the UK biologics sector.
The NBMC is used for developing biopharmaceuticals and biologics using biotechnology. Production of biologic products needs to have biological foundations such as cells, bacteria, yeast and others to perform precise development processes. The new facility is equipped with all such tools, facilities and technology for the development of innovative biologic medicines.
Construction on the National Biologics Manufacturing Centre started in April 2014 and the facility was opened in September 2015.
The £38m ($64m) design-and-build contract was awarded to Interserve Construction, a company based in Darlington, in March 2014.
The UK-based Centre for Process Innovation (CPI) provides guidance to companies to develop new products and processes from concept to finished product. It uses applied knowledge in science and engineering together with sophisticated development facilities. It enables clients to develop, demonstrate, prototype and scale-up the next generation of biologic products and processes.
CPI was made part of the High Value Manufacturing Catapult (HVMC) network, which consists of seven technology and innovation centres, in 2011. The HVMC was established in the UK to access the best manufacturing talent and facilities.
Biological medicines account for 10% to 15% of pharmaceutical market and constitute more than one-fifth of new medicines launched in worldwide every year. The new facility at Darlington helps the UK to expand its contribution to the high value and high-quality production of biologic medicines in the global market.
Thermo Fisher Scientific (Thermo Fisher) will establish a new pharmaceutical services facility for integrated biologics and sterile drug development and…
Arranta Bio is constructing a new multi-product, commercial-ready manufacturing facility in Watertown, Massachusetts, US. Watertown facility will be used for…
Berkshire Sterile Manufacturing (BSM) is expanding its manufacturing facility in Lee, Massachusetts (MA), US. The company began preparations for the…
Lykan Bioscience opened a purpose-built SMART Manufacturing™ facility for developing cell-based therapies in Hopkinton, Massachusetts, US, in September 2020. The…